Friedreich’s ataxia (FA) is a rare genetic neurodegenerative disorder with the majority of cases involving expansion of a trinucleotide sequence in the gene coding for the protein fraxatin. Symptoms usually appear during childhood or adolescence as unsteadiness of gait which progresses into inability to walk independently within a few years, alongside other signs and symptoms. There are also cases of late-onset FA in which symptoms appear in middle age. Untreated FA results in limited life expectancy with death occurring due to multisystem complications and trauma sequelae, although the current therapies have significantly improved the average survival of FA patients.
This report provides the current prevalent population for FA across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Austria, Switzerland, Ireland, Russia, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, FA patients grouped by genetic features and symptoms have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of FA include:
- Left ventricular hypertrophy
- Supraventricular tachycardias
- Cognitive deficits
- Affective disorders
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Ability to quantify patient populations in global FA market to target the development of future products, pricing strategies and launch plans.
- Further insight into the prevalence of the subdivided types of FA and identification of patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Better understanding of the impact of specific co-morbid conditions on the prevalent population of FA patients.
- Identification of FA patient sub-populations that require treatment.
- Better understanding of the specific markets that have the largest number of FA patients.